212 related articles for article (PubMed ID: 10961897)
1. Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines.
Jonuleit T; van der Kuip H; Miething C; Michels H; Hallek M; Duyster J; Aulitzky WE
Blood; 2000 Sep; 96(5):1933-9. PubMed ID: 10961897
[TBL] [Abstract][Full Text] [Related]
2. BCR/ABL regulates expression of the cyclin-dependent kinase inhibitor p27Kip1 through the phosphatidylinositol 3-Kinase/AKT pathway.
Gesbert F; Sellers WR; Signoretti S; Loda M; Griffin JD
J Biol Chem; 2000 Dec; 275(50):39223-30. PubMed ID: 11010972
[TBL] [Abstract][Full Text] [Related]
3. The tyrosine kinase inhibitor CGP 57148 (ST1 571) induces apoptosis in BCR-ABL-positive cells by down-regulating BCL-X.
Oetzel C; Jonuleit T; Götz A; van der Kuip H; Michels H; Duyster J; Hallek M; Aulitzky WE
Clin Cancer Res; 2000 May; 6(5):1958-68. PubMed ID: 10815921
[TBL] [Abstract][Full Text] [Related]
4. BCR-ABL induces the expression of Skp2 through the PI3K pathway to promote p27Kip1 degradation and proliferation of chronic myelogenous leukemia cells.
Andreu EJ; Lledó E; Poch E; Ivorra C; Albero MP; Martínez-Climent JA; Montiel-Duarte C; Rifón J; Pérez-Calvo J; Arbona C; Prósper F; Pérez-Roger I
Cancer Res; 2005 Apr; 65(8):3264-72. PubMed ID: 15833859
[TBL] [Abstract][Full Text] [Related]
5. Histone deacetylase inhibitor LAQ824 both lowers expression and promotes proteasomal degradation of Bcr-Abl and induces apoptosis of imatinib mesylate-sensitive or -refractory chronic myelogenous leukemia-blast crisis cells.
Nimmanapalli R; Fuino L; Bali P; Gasparetto M; Glozak M; Tao J; Moscinski L; Smith C; Wu J; Jove R; Atadja P; Bhalla K
Cancer Res; 2003 Aug; 63(16):5126-35. PubMed ID: 12941844
[TBL] [Abstract][Full Text] [Related]
6. Abnormal integrin-mediated regulation of chronic myelogenous leukemia CD34+ cell proliferation: BCR/ABL up-regulates the cyclin-dependent kinase inhibitor, p27Kip, which is relocated to the cell cytoplasm and incapable of regulating cdk2 activity.
Jiang Y; Zhao RC; Verfaillie CM
Proc Natl Acad Sci U S A; 2000 Sep; 97(19):10538-43. PubMed ID: 10973491
[TBL] [Abstract][Full Text] [Related]
7. Role of BCR-ABL-Y177-mediated p27kip1 phosphorylation and cytoplasmic localization in enhanced proliferation of chronic myeloid leukemia progenitors.
Chu S; McDonald T; Bhatia R
Leukemia; 2010 Apr; 24(4):779-87. PubMed ID: 20200561
[TBL] [Abstract][Full Text] [Related]
8. BCR-ABL and interleukin 3 promote haematopoietic cell proliferation and survival through modulation of cyclin D2 and p27Kip1 expression.
Parada Y; Banerji L; Glassford J; Lea NC; Collado M; Rivas C; Lewis JL; Gordon MY; Thomas NS; Lam EW
J Biol Chem; 2001 Jun; 276(26):23572-80. PubMed ID: 11323429
[TBL] [Abstract][Full Text] [Related]
9. The Jab1/COP9 signalosome subcomplex is a downstream mediator of Bcr-Abl kinase activity and facilitates cell-cycle progression.
Tomoda K; Kato JY; Tatsumi E; Takahashi T; Matsuo Y; Yoneda-Kato N
Blood; 2005 Jan; 105(2):775-83. PubMed ID: 15353483
[TBL] [Abstract][Full Text] [Related]
10. Requirement for Mdm2 in the survival effects of Bcr-Abl and interleukin 3 in hematopoietic cells.
Goetz AW; van der Kuip H; Maya R; Oren M; Aulitzky WE
Cancer Res; 2001 Oct; 61(20):7635-41. PubMed ID: 11606405
[TBL] [Abstract][Full Text] [Related]
11. Persistent Cdk2 inactivation drives growth arrest of BCR-ABL-expressing cells in response to dual inhibitor of SRC and ABL kinases SKI606.
Mancini M; Brusa G; Zuffa E; Corrado P; Martinelli G; Grafone T; Barbieri E; Santucci MA
Leuk Res; 2007 Jul; 31(7):979-87. PubMed ID: 17129604
[TBL] [Abstract][Full Text] [Related]
12. A member of Forkhead transcription factor FKHRL1 is a downstream effector of STI571-induced cell cycle arrest in BCR-ABL-expressing cells.
Komatsu N; Watanabe T; Uchida M; Mori M; Kirito K; Kikuchi S; Liu Q; Tauchi T; Miyazawa K; Endo H; Nagai T; Ozawa K
J Biol Chem; 2003 Feb; 278(8):6411-9. PubMed ID: 12456669
[TBL] [Abstract][Full Text] [Related]
13. BCR-ABL but not JAK2 V617F inhibits erythropoiesis through the Ras signal by inducing p21CIP1/WAF1.
Tokunaga M; Ezoe S; Tanaka H; Satoh Y; Fukushima K; Matsui K; Shibata M; Tanimura A; Oritani K; Matsumura I; Kanakura Y
J Biol Chem; 2010 Oct; 285(41):31774-82. PubMed ID: 20663870
[TBL] [Abstract][Full Text] [Related]
14. BCR signals target p27(Kip1) and cyclin D2 via the PI3-K signalling pathway to mediate cell cycle arrest and apoptosis of WEHI 231 B cells.
Banerji L; Glassford J; Lea NC; Thomas NS; Klaus GG; Lam EW
Oncogene; 2001 Nov; 20(50):7352-67. PubMed ID: 11704865
[TBL] [Abstract][Full Text] [Related]
15. Direct relation between BCR-ABL tyrosine kinase activity and cyclin D2 expression in lymphoblasts.
Deininger MW; Vieira SA; Parada Y; Banerji L; Lam EW; Peters G; Mahon FX; Köhler T; Goldman JM; Melo JV
Cancer Res; 2001 Nov; 61(21):8005-13. PubMed ID: 11691826
[TBL] [Abstract][Full Text] [Related]
16. Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-alpha bigenic mice.
Lenferink AE; Simpson JF; Shawver LK; Coffey RJ; Forbes JT; Arteaga CL
Proc Natl Acad Sci U S A; 2000 Aug; 97(17):9609-14. PubMed ID: 10931950
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: implications for CML.
O'Hare T; Pollock R; Stoffregen EP; Keats JA; Abdullah OM; Moseson EM; Rivera VM; Tang H; Metcalf CA; Bohacek RS; Wang Y; Sundaramoorthi R; Shakespeare WC; Dalgarno D; Clackson T; Sawyer TK; Deininger MW; Druker BJ
Blood; 2004 Oct; 104(8):2532-9. PubMed ID: 15256422
[TBL] [Abstract][Full Text] [Related]
18. A model of human p210(bcr/ABL)-mediated chronic myelogenous leukemia by transduction of primary normal human CD34(+) cells with a BCR/ABL-containing retroviral vector.
Zhao RC; Jiang Y; Verfaillie CM
Blood; 2001 Apr; 97(8):2406-12. PubMed ID: 11290604
[TBL] [Abstract][Full Text] [Related]
19. Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML): evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides.
Aichberger KJ; Mayerhofer M; Krauth MT; Skvara H; Florian S; Sonneck K; Akgul C; Derdak S; Pickl WF; Wacheck V; Selzer E; Monia BP; Moriggl R; Valent P; Sillaber C
Blood; 2005 Apr; 105(8):3303-11. PubMed ID: 15626746
[TBL] [Abstract][Full Text] [Related]
20. Absence of SKP2 expression attenuates BCR-ABL-induced myeloproliferative disease.
Agarwal A; Bumm TG; Corbin AS; O'Hare T; Loriaux M; VanDyke J; Willis SG; Deininger J; Nakayama KI; Druker BJ; Deininger MW
Blood; 2008 Sep; 112(5):1960-70. PubMed ID: 18559973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
